Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Expands By 314.4%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 11,113 shares, a growth of 314.4% from the April 30th total of 2,682 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 14,125 shares, the short-interest ratio is presently 0.8 days.

Santen Pharmaceutical Stock Down 2.2%

OTCMKTS SNPHY opened at $11.72 on Friday. The company has a market capitalization of $3.78 billion and a P/E ratio of 0.10. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $12.68. The firm has a 50-day moving average price of $11.22 and a two-hundred day moving average price of $10.85.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, Santen Pharmaceutical currently has an average rating of “Hold”.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.